US20170190750A1 - Peptide for Protection of Allergic Respiratory Disorders - Google Patents
Peptide for Protection of Allergic Respiratory Disorders Download PDFInfo
- Publication number
- US20170190750A1 US20170190750A1 US15/406,535 US201715406535A US2017190750A1 US 20170190750 A1 US20170190750 A1 US 20170190750A1 US 201715406535 A US201715406535 A US 201715406535A US 2017190750 A1 US2017190750 A1 US 2017190750A1
- Authority
- US
- United States
- Prior art keywords
- peptide
- antibody
- mammal
- horses
- rao
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 62
- 208000028004 allergic respiratory disease Diseases 0.000 title description 2
- 241000283073 Equus caballus Species 0.000 claims abstract description 50
- 241000282414 Homo sapiens Species 0.000 claims abstract description 33
- 229960005486 vaccine Drugs 0.000 claims abstract description 25
- 210000002966 serum Anatomy 0.000 claims abstract description 16
- 102100031083 Uteroglobin Human genes 0.000 claims abstract 5
- 108090000203 Uteroglobin Proteins 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims description 31
- 241000124008 Mammalia Species 0.000 claims description 27
- 239000002671 adjuvant Substances 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 14
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 13
- 208000026935 allergic disease Diseases 0.000 claims description 12
- 230000000241 respiratory effect Effects 0.000 claims description 9
- 208000023504 respiratory system disease Diseases 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract description 100
- 101710176384 Peptide 1 Proteins 0.000 abstract description 99
- 241000283086 Equidae Species 0.000 abstract description 93
- 208000006673 asthma Diseases 0.000 abstract description 55
- 238000009169 immunotherapy Methods 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 208000011623 Obstructive Lung disease Diseases 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 210000004899 c-terminal region Anatomy 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000007924 injection Substances 0.000 description 50
- 238000002347 injection Methods 0.000 description 50
- 101000777234 Mesocricetus auratus Uteroglobin Proteins 0.000 description 34
- 239000000427 antigen Substances 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 241000700198 Cavia Species 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 230000004044 response Effects 0.000 description 14
- 239000013566 allergen Substances 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 241000283707 Capra Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000007613 environmental effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 208000000884 Airway Obstruction Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 description 7
- 102000013415 peroxidase activity proteins Human genes 0.000 description 7
- 230000000306 recurrent effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 229960004784 allergens Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000006957 competitive inhibition Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000036428 airway hyperreactivity Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 210000004731 jugular vein Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000003118 sandwich ELISA Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 108010058643 Fungal Proteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 102000011195 Profilin Human genes 0.000 description 3
- 108050001408 Profilin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 206010048908 Seasonal allergy Diseases 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000055576 human SCGB1A1 Human genes 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 230000035874 hyperreactivity Effects 0.000 description 2
- 230000004047 hyperresponsiveness Effects 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000013105 post hoc analysis Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 210000002265 sensory receptor cell Anatomy 0.000 description 2
- 102000027509 sensory receptors Human genes 0.000 description 2
- 108091008691 sensory receptors Proteins 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- QWVRTSZDKPRPDF-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)-3-pyridin-3-yl-5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CCCCN1CC(N=1)CONC=1C1=CC=CN=C1 QWVRTSZDKPRPDF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102100036327 Glucose-6-phosphatase 3 Human genes 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000930935 Homo sapiens Glucose-6-phosphatase 3 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000739178 Homo sapiens Secretoglobin family 3A member 2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001293415 Mannheimia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001295810 Microsporidium Species 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241000122990 Nosema ceranae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241001134661 Saccharopolyspora rectivirgula Species 0.000 description 1
- 102100037269 Secretoglobin family 3A member 2 Human genes 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000123579 Xenorhabdus bovienii Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000021240 acute bronchiolitis Diseases 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960001113 butorphanol Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000005120 human airway smooth muscle cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000004335 respiratory allergy Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004878 submucosal gland Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960004175 xylazine hydrochloride Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Definitions
- This invention pertains to a unique peptide isolated from horse CC10 that can be used as a vaccine to protect horses from recurrent airway obstruction (RAO) and also to antibodies to this peptide which can be used in passive immunotherapy for short term protection against RAO or in assays to determine the level of CC10 protein in mammals.
- This new peptide can also be used to protect humans from asthma, based on the similarity between horse RAO and human asthma.
- Recurrent Airway Obstruction a respiratory disease similar to human asthma, is one of the most commonly diagnosed conditions affecting the lung of older horses all around world. It is a type-1 immediate hypersensitivity allergic disease involving a series of events that begin with reaginic antibodies, mainly IgE. These antibodies bind with high affinity to Fc epsilon-RI (Fc ⁇ RI) receptors via the Fc portion that are found on the membrane of mast cells and basophils. Once bound, the antibodies can cross-link with environmental allergens, resulting in mast cell degranulation leading to the production of histamine and other chemical mediators that act together to induce airway inflammation.
- Fc ⁇ RI Fc epsilon-RI
- At least one reaginic antibody against Faenia rectivirgula was found to be associated with lung diseases in RAO-affected and unaffected horses, finding the antibody present in about 15% in RAO-affected horses (28).
- RAO is the result of a pulmonary hypersensitivity to inhaled antigens. Exposure of affected horses to hay dust, pollens, and mold spores leads to neutrophil accumulation in the lung and bronchospasm. The identification of allergen-specific IgE in bronchoalveolar lavage (BAL) fluid and sera of affected horses supports the involvement of a late phase, IgE-mediated, hypersensitivity reaction in the pathogenesis of equine RAO. The cytokine profiles of horse affected by RAO have been measured, and a modified Th2-like immune response was thought to be involved with elevated IL-4, IL-13 and IFNg levels (6,22).
- BAL bronchoalveolar lavage
- Clara Cell 10 kDa protein is one of the members of a family of anti-inflammatory defense proteins produced predominantly in the airway epithelium of man and animals. In humans it is also called human uteroglobin (See U.S. Pat. Nos. 6,255,281 and 7,846,899). CC10 has been shown to inhibit the entry of eosinophils and neutrophils into the human airways during inflammation in the lung, and to inhibit enzymes that release inflammatory mediators (23). Some of the members of this family have been directly linked to protection from asthma, allergy and related inflammatory responses. The gene that encodes the protein was found to be down regulated during RAO in horses (34), and the production of the CC 10 protein was also reported to be reduced in RAO horses (24).
- the amount of CC10 in the horse serum was measured using antibodies produced in rabbits using a synthetic 21 amino acid peptide from horse CC10 (EPSKPDADMKAATTQLKTLV; SEQ ID NO:2). This peptide corresponded to amino acids 47-66 of horse CC10 protein (protein accession no. NP 001075327.1) with two amino acid variations.
- a hypo-allergic vaccine to an environmental antigen of Timothy grass pollen Profilins was developed by engineering its structure (35). The engineered protein was demonstrated to induce IgG's and inhibit allergic patients' IgE antibody binding to Profilins to a similar degree as those induced by immunization with the wild type. IgG's inhibited Profilin-induced basophil degranulation.
- Another environmental antigen, a novel Fel d1 cat allergy vaccine, was developed that induced strong IgG response, which abrogated the allergy response in mice (32). Allergen-induced systemic basophil degranulation was shown inhibited in an Fc gamma-RIIb-dependent manner (26).
- Fc gamma-R's Fc fragment of immunoglobulin-G
- Fc gamma-R's are important molecules not only to mediate and control the effectors' functions of IgG antibodies, but they also control the autoimmunity-tolerance balance in the periphery.
- Fc gamma-R's belonging to the immunoglobulin gene super-family have been identified via Fc gamma-RI (CD64), Fc gamma-RII (CD32) and Fc gamma-RIII (CD16).
- myeloid cells express both activating and inhibitory receptors of the Fc gamma-RII family.
- Fc gamma-RIIA mediates processes associated with cell activation, while Fc gamma-RIIB down regulates such signaling. Differences in affinity for IgG between activating and inhibitory Fc gamma-R can result in substantial local changes in their relative concentrations with important functional consequences.
- Human airway smooth muscle cells express IgG-Fc gamma-RIIb with the potential to suppress remodeling and immune-modulation (36).
- a wide range of inflammatory and autoimmune diseases such as vasculitis, glomerulonephritis, and autoimmune hemolytic anemia, seems to be mediated, in part, by Fc gamma-R's.
- mice which again are not naturally susceptible to asthma, but asthma can be induced experimentally.
- One advantage to mice is the ability to study the genetic aspects of the disease (12).
- Equine models of human asthma A major advantage to an equine model is that horses get asthma naturally like people. Horses are important for the similarity between the signs and symptoms of recurrent airway obstruction (RAO) to those of asthma, for the similarity in the nature of disease progression to human asthma, and for the ability in horses to induce or precipitate an “asthmatic” episode (7,33). Histological findings such as thickening of epithelial basement membrane, edema, inflammatory infiltrate in bronchial walls, oversized submucosal glands, hypertrophy of bronchial wall muscle, and emphysematous changes are observed in both human asthma and in equine RAO (6,7,33).
- RAO chronic obstructive pulmonary disease
- COPD chronic obstructive pulmonary disease
- RAO recurrent airway obstruction
- Heaves is a more common condition in temperate climatic regions where horses are confined in stables during winter seasons and where they are house near stored hay.
- Another form of RAO seen in the southern regions of the U.S. is summer pasture-associated obstructive pulmonary disease (SPAOPD), caused by allowing horses to graze on lush pasture in the humid summer months where molds and pollens in the grass serve as antigen stimulation (4). Both forms of RAO share common signs and symptoms (4,6,11).
- the clinically abnormal condition of RAO is characterized by hyperreactivity of airways to antigens, inflammatory mediators and various other external stimuli.
- the condition also presents a decreased dynamic compliance of lung and increased airflow resistance to histamine- or methacholine-challenges, which are the common tests performed for diagnosing either human asthma or equine RAO.
- histamine- or methacholine-challenges are the common tests performed for diagnosing either human asthma or equine RAO.
- horses are exposed to diverse stimuli such as allergens or respirable irritants in the environment, their airways react with a specific response that includes infiltration of inflammatory cells in the lungs, damage of airway epithelium, and inflammatory mediator release. This reaction primes the airways to respond excessively to a broader range of stimuli.
- U.S. Patent Application Publication No. 2011/0240012 describes the use of recombinant human CC10 and methods to administer CC10 nasally, and its use in treatment of various nasal inflammatory diseases, including rhinitis and sinusitis.
- aa 21 amino acid (aa) peptide (Peptide-1; SEQ ID NO: 1; KNTKDSILKLMDKIAKSPLCA) based on the C-terminal of Equine CC10 that can be used as a vaccine to protect horses from RAO, and protect humans from asthma.
- a rabbit polyclonal antibody to this peptide was produced, and validated the specificity of antibody by ELISA.
- Peptide-1 may be used in young animals as a vaccine to protect them from RAO later in life; (2) antibodies to Peptide-1 may be administered for short-term passive immunotherapy to RAO-affected horses; and (3) antibodies to Peptide-1 can be used in measuring the level of CC10 protein in animals to identify potential RAO horses (horses with reduced CC10).
- antibodies to Peptide-1 can be used in measuring the level of CC10 protein in animals to identify potential RAO horses (horses with reduced CC10).
- human seasonal allergy or asthma
- this Peptide-1 or homologous sequences or its antibodies may be useful therapeutically in humans for protection against or alleviating the symptoms of asthma.
- FIG. 1 illustrates the results of an antibody capture endpoint ELISA showing the Peptide-1 specific antibody titer with Peptide-1 as the capture antigen, peroxidase-conjugated goat anti-rabbit IgG as the detection antibody, and the isolated rabbit antibody at several dilutions.
- FIG. 2 illustrates the results of a competitive inhibition ELISA assay using a series of concentrations of Peptide-1.
- FIG. 3 illustrates the amount of CC10 IgG titer from five healthy horses (without RAO) as compared to the control as measured using competitive inhibition ELISA assay.
- FIG. 4 illustrates the amount of Peptide-1 specific IgG titer using a direct sandwich ELISA and measuring serum from eight healthy horses standardizing the value by subtracting the control value of UGRP peptide from the experimental values for CC10.
- FIG. 5A illustrates the amount of Peptide-1 specific IgG titer in serum from Foal #2 primed on day 0 and boosted on day 29 by subcutaneous injection of 0.1 mg/kg Peptide-1.
- Antibody titer determined using a direct sandwich end point ELISA with Peptide-1 as a capture antigen and peroxidase conjugated goat anti-equine IgG as a detection antibody.
- FIG. 5B illustrates the amount of Peptide-1 specific IgG titer in serum from Foal #3 primed on day 0 and boosted on day 29 by subcutaneous injection of 0.1 mg/kg Peptide-1.
- Antibody titer determined using a direct sandwich end point ELISA with Peptide-1 as a capture antigen and peroxidase conjugated goat anti-equine IgG as a detection antibody.
- Peptide-1 refers to a 21 amino acid (aa) peptide (Peptide-1; SEQ ID NO: 1; KNTKDSILKLMDKIAKSPLCA) based on the C-terminal of Equine CC10 that can be used as a vaccine to protect mammals from a respiratory airway disorder.
- This invention relates not only to a functional Peptide-1 as described in this specification, but also to peptides having modifications to such a sequence resulting in an amino acid sequence having the same function (i.e., the ability to be used as a vaccine for protection against antigen-caused respiratory disorders), and about 80%, preferably 85%, and more preferably 90% homology to the sequence of the amino acid sequence as described, and most preferably about 95% or greater homology, particularly in conserved regions.
- “Homology” as used here means identical amino acids or conservative substitutions (e.g., acidic for acidic, basic for basic, polar for polar, nonpolar for nonpolar, aromatic for aromatic).
- the degree of homology can be determined by simple alignment based on programs known in the art, such as, for example, GAP and PILEUP by GCG, or the BLAST software available through the NIH interne site. Most preferably, a certain percentage of “homology” would be that percentage of identical amino acids.
- vaccine refers to a composition or compound (an antigen) used to stimulate an immune response in a mammal and so confer resistance to the disease or infection in that mammal, including an ability of the immune system to remember the previously encountered antigen.
- Antibodies are produced as a result of the first exposure to an antigen and stored in the event of subsequent exposure.
- adjuvant refers to non-antigenic substance that, in combination with an antigen, enhances antibody production by inducing an inflammatory or other non-defined response, which leads to a local influx of antibody-forming cells.
- adjuvants are used therapeutically in the preparation of vaccines, since they increase the production of antibodies against small quantities of antigen, lengthen the period of antibody production, and tend to induce memory cell responses.
- Such adjuvants could include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, aluminium hydroxide, dimethyldioctadecylammonium bromide, Adjuvax (Alpha-Beta Technology), Imject Alum (Pierce), Monophosphoryl Lipid A (Ribi Immunochem Research), MPL+TDM (Ribi Immunochem Research), Titermax (CytRx), toxins, toxoids, glycoproteins, lipids, glycolipids, bacterial cell walls, subunits (bacterial or viral), carbohydrate moieties (mono-, di-, tri- tetra-, oligo- and polysaccharide) various liposome formulations or saponins.
- Alum is the adjuvant currently in use for human patients. However, for horses, incomplete Freund's adjuvant may be used.
- immune response refers to the reaction of the body to an antigen, which is usually a foreign or potentially dangerous substances (antigens), particularly disease-producing microorganisms.
- antigens a foreign or potentially dangerous substances
- CC10 endogenously produced defense protein
- the response involves the production by specialized white blood cells (lymphocytes) of proteins known as antibodies, which react with the antigens to render them harmless.
- the antibody-antigen reaction is highly specific. Vaccines also stimulate immune responses.
- immunologically effective amount refers to the quantity of an immune response inducing substance required to induce the necessary immunological memory required for an effective vaccine.
- Peptide-1 at a dose of 0.1 mg/kg body weight when given subcutaneously has been found an immunologically effective amount.
- compositions of the present invention are advantageously administered in the form of injectable compositions.
- a typical composition for such purpose comprises a pharmaceutically acceptable carrier.
- the composition may contain human serum albumin in a phosphate buffer containing NaCl.
- Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like (REMINGTON'S PHARMACEUTICAL SCIENCES, 15th Ed., Easton ed., Mack Publishing Co., pp 1405-1412 and 1461-1487 (1975) and THE NATIONAL FORMULARY XIV, 14th Ed., American Pharmaceutical Association, Washington, D.C. (1975), both hereby incorporated by reference).
- non-aqueous solvents examples include propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyloleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, etc.
- Intravenous vehicles include fluid and nutrient replenishers. The pH and exact concentration of the various components the pharmaceutical composition are adjusted according to routine skills in the art. Goodman and Gilman, THE PHARMACOLOGICAL BASIS FOR THERAPEUTICS (7th ed.).
- the peptide may be covalently linked to an immunogenic protein carrier to increase its recognition by the immune system as foreign.
- immunogenic protein carriers include keyhole limpet hemocyanin (KLH).
- KLH keyhole limpet hemocyanin
- BSA Bovine serum albumin
- OVA chicken egg albumin
- Fc fragment immunoglublin Fc fragment.
- non-proteinic nanoparticles have been used as carriers.
- such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared.
- the preparation also may be emulsified.
- the active immunogenic ingredient is often mixed with an excipient that is pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
- the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH-buffering agents, adjuvants or immunopotentiators that enhance the effectiveness of the vaccine.
- the vaccines are conventionally administered intraperitoneally, intramuscularly, intradermally, subcutaneously, orally, nasally, or parenterally. Additional formulations are suitable for other modes of administration and include oral formulations. Oral formulations include such typical excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. Additionally, the peptide can be encapsulated in a sustained release formulations or a coating that resist the acidic pH of the stomach.
- the compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25-70%.
- Peptide-1 conjugated with KLH and Incomplete Freund's adjuvant were used in a subcutaneous injection.
- Other possible routes of administration is to use a DNA expression vector with a nucleic acid sequence encoding the Peptide 1 (SEQ ID NO:1) for immunization using intradermal or intramuscular techniques.
- the dose to be administered depends on a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent, i.e., carrier or vehicle, and a particular treatment regimen.
- the quantity to be administered both according to number of treatments and amount, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and degree of protection desired.
- the precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosage ranges are on the order of one to several hundred micrograms of active ingredient per individual subject.
- Suitable regimes for initial administration and booster shots also vary but are typified by an initial administration followed in one or two week intervals by one or more subsequent injections or other administration. Annual boosters may be used for continued protection.
- An isolated 21-amino acid peptide was designed and made based on the ‘C’ terminal 21 amino acid peptide of Equine CC10 protein (Accession no. NP_001075327.1) (“Peptide-1; SEQ ID NO:1; KNTKDSILKLMDKIAKSPLCA). The sequence of this peptide corresponds to amino acids 71-91 of equine CC10 and does not overlap with that of the peptide (amino acids 47-66) previously used to make rabbit antibodies (24). Peptide-1 was used to develop rabbit polyclonal antibodies.
- Peptide-1 was conjugated to the carrier protein KLH (Keyhole Limpet Hemocyanin), and the conjugate used to immunize na ⁇ ve rabbits to induce an immune response.
- Antibodies were purified from serum of immunized rabbits by established chromatographic techniques as described previously (21). The rabbit antibody was verified in an antibody capture endpoint Enzyme-Linked ImmunoSorbent Assay (ELISA) with Peptide-1 as the capture antigen and peroxidase conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa.) as the detection antibody as described previously (9).
- ELISA Enzyme-Linked ImmunoSorbent Assay
- the rabbit antibody had a titer of >100,000 with an optimum detection range between 1000 and 10,000 dilutions ( FIG. 1 ).
- a 1 : 5000 dilution of this antibody was used for further CC10 detection in a competitive ELISA.
- a series of Peptide-1 dilutions starting at 1000 ⁇ g/mL was prepared. From each dilution, 50 ⁇ L was mixed with 50 ⁇ L of a solution of 1:5000 diluted rabbit polyclonal antibody. This mixture was incubated for 30 min, and then used in ELISA with a Peptide-1 coated plate as described previously (9). As shown in FIG. 2 , the inhibition of antibody binding to peptide coated plated was dependent on Peptide-1 concentration.
- the competitive ELISA system as described above was used to measure relative levels of CC10 in the serum of 5 healthy and 5 RAO horses. Briefly, 10 ⁇ L of serum from each horse was mixed with 50 ⁇ L of a 1:5000 diluted rabbit antibody to Peptide-1 and incubated at 37° C. for 30 min. This serum-antibody mixture was then added to wells on ELISA plate pre-coated with Peptide-1 and blocked with 2% milk powder proteins (Carnation Milk, Nestle). The amount of free peptide specific rabbit antibody available to bind to Peptide-1 coated on the plate varied, depending on the amount of native CC 10 present in the scrum sample.
- the Peptide-1 sequence was used in a protein BLAST sequence analysis against published bacterial and fungal proteins. High homology to some bacterial and fungal proteins including to Aspergillus , a known environmental allergen was found. (Table 1).
- the hygiene hypothesis suggests that a reduced frequency of infections, less severe infection, and prevention of infection (for example, by a frequent use of antibiotics) would prevent maturation of Th-1 immunity and, therefore, would give rise to an allergen-specific Th-2 immune response following natural exposure to allergens.
- the immunological explanation for the “hygiene hypothesis” has been proposed to be the induction of T helper 1 (Th1) responses by microbial products.
- Th1 T helper 1
- the hygiene hypothesis has been proposed to be more important in regulating the PMN-dominant inflammatory response than in inducing a Th1-dominant response (10).
- Endotoxins part of the outer membrane of Gram negative bacteria, are a potent inducer of neutrophilic airway inflammation.
- the risk of non-atopic asthma, characterized by neutrophilic response, is enhanced in subjects with higher endotoxin exposure. This information is in accordance with the so-called hygiene hypothesis and have been supported by animal studies and at the cellular level (11).
- vaccinating the horses at a young age with Peptide-1 will produce protective immune response which will protect them from environmental allergens.
- Peptide-1 can be used as a vaccine for young horses to protect them from developing the respiratory allergy later in their life.
- the antibody produced to Peptide-1 can be used in passive immunotherapy for short term therapy to decrease the symptoms of a horse or other mammal with respiratory airway disease.
- Antibodies to Peptide-1 can also be used to determine the level of CC10 protein in horses. A decreased level of CC10 in the serum could be a biomarker for detecting horses that are vulnerable to RAO which will facilitate early selection and improved breeding.
- Peptide-1 or similar peptide may also be useful in developing a vaccine to protect people that are susceptible to allergic diseases such as human asthma.
- the foals were selected based on a thorough physical examination by a board certified equine clinician and a complete blood count (CBC) was performed to determine any clinical pathology.
- Peptide-1 is a small peptide, it was covalently conjugated with a large carrier protein, Keyhole Limpet Hemocyanin (KLH), for easy recognition by the lymphocytes to produce antibody production.
- KLH is a commonly used as a carrier protein.
- the first foal was used to test the injection method and dosage.
- a low dose of 0.1 mg/kg body weight of conjugated peptide-1 with KLH was used, but without an adjuvant to minimize any adverse reactions due to either a high dose of peptide-1 or adjuvant.
- This protocol allowed a determination of any reaction due to the conjugated peptide-1 alone.
- a subcutaneous route of administration was chosen to produce a consistent “slow and steady” absorption.
- the first injection was given on the left side of the neck after cleaning with alcohol. No major adverse reaction was observed at the site of injection or on the animal as a whole. A small swelling was observed at the site of injection which disappeared after two days.
- the foal did not have any fever or any other clinical pathological changes.
- the peptide-1 specific total IgG antibody titers were determined in the serum samples by enzyme labeled immune sorbent assay (ELISA). So far, eight samples have been tested in this foal for a time period of 57 days. The results are shown in FIG. 5A . The samples were taken on pre-injection serum collected on day 0, and then every seven days thereafter. The results indicate that the antibody titer to Peptide-1 increased exponentially after day 15 up to day 22, when there was a drop. After the booster on day 29, the antibody titer increased to a peak level at day 36, but remained at elevated levels for the remaining period. As shown in FIG.
- Peptide-1 at a dose of 0.1 mg/kg when injected subcutaneously with an adjuvant can produce significant amounts of antibodies.
- RAO recurrent airway obstruction
- Foal #3 is still being followed.
- the results to date are shown in FIG. 5B .
- the antibody titer did not increase until about day 15, similar to Foal #2. It then peaked on day 22, and then again after the booster on day 29.
- the response curve for this foal closely follows the response curve of Foal #2, confirming the effectiveness of Peptide-1 in producing antibodies.
- Peptide-1 will be used to vaccinate adult horses, or antibodies to Peptide-1 will be used for short term protection for adult horses.
- Initial experiments will determine the effectiveness of use of the peptide or its antibody to protect adult horses from recurrent airway obstruction (RAO).
- RAO recurrent airway obstruction
- Experiments to achieve the following three objectives will be conducted: (1) a determination of the antibody levels in horses that receive two subcutaneous injections of the peptide one month apart; (2) a determination of whether the horses can maintain a sufficient titer of antibody for immunity from an injection given during the remission period; and (3) a determination of whether horses that receive the peptide injection or an injection of antibodies are resistant to RAO or develop lesser symptoms of RAO.
- the antibodies will be extracted from the blood of foals that were injected with Peptide-1 as described above. A onetime collection of blood of 450 ml from each foal will be collected. If adult horses, as expected, maintain high antibody titer values after injection of Peptide-1, antibody from the adult horses can also be used. The sera with high antibody titers value will be pooled for purification and antibody extraction.
- Transpleural pressure determination The change in transpleural pressure (Ppl) will be measured indirectly as previously described (31,34). Briefly, a 10-cm long 3.5-cm circumference esophageal balloon will be secured at one end of a catheter (PE tubing 350). The catheter will be connected to a pressure transducer (model PESO) interfaced with a polygraph (Grass model 7D). The balloon will be inserted through a lubricated nasogastric tube (bigger tube) placed in the rostral esophagus. Once the balloon is located between the heart and the diaphragm, the nasogastric tube will be removed. The balloon will be inflated with 1.5 ml of water, and 10 measurements will be recorded.
- Bronchoalveolar lavage (BAL) fluid collection Horses will be sedated using a combination of xylazine hydrochloride (0.5 mg/kg, given intravenously (IV)) and butorphanol tartarate (11 mg/kg, IV). After placement of a nose twitch, a 244-cm (11-mm outer diameter, 3-mm inner diameter) flexible silicone tube will be passed through the nasal passage into the trachea to wedge in the distal airway. As the silicone tube is advanced through the trachea and carina, 36 mL of 1% lidocaine will be injected through the tube and followed by 30 mL of air.
- xylazine hydrochloride 0.5 mg/kg, given intravenously (IV)
- butorphanol tartarate 11 mg/kg, IV.
- a 244-cm (11-mm outer diameter, 3-mm inner diameter) flexible silicone tube will be passed through the nasal passage into the trachea to wedge in the distal airway.
- the cuff will be inflated with 4 mL of air, and five 60-mL aliquots of sterile 0.9% saline will be infused manually with 60 mL syringes. Immediately after infusion, bronchoalveolar lavage fluid (BALF) will be collected and pooled into a sterile flask. Cytological analysis of BAL fluid will demonstrate whether the horses have any other respiratory problem (10,31)
- Clinical Scoring The horses will be assigned a clinical score (CS).
- the CS is determined by the following algorithm (31, 34.
- Each of these variables in the formula is scored from 0 to 4.
- the zero score indicates the nostril has little movement, and the ventral flank shows little or no movement.
- a score of 4 indicates the nostril remains maximally flared throughout the respiratory cycle and abdominal lift resulting in a “heave line” extending cranially to the 5 th intercostal space.
- the maximum CS is 8.
- Clinically healthy horses will have clinical scores ⁇ 4.0.
- RAO horses will have a score of >5.0. This non-invasive procedure will show whether the animal has RAO.
- Foals that have previously injected with Peptide-1 will be used to supply antibodies to Peptide-1 as discussed above.
- a one-time sample of 450 ml blood will be collected from each foal, all of whom are currently above 200 lb body weight.
- 10 ml blood will be collected from the adult horses before the injection (peptide or antibody) and weekly thereafter until the season (June, July, August) is over.
- Antibody extraction Total IgG antibody from hyper-immune sera collected from foals will be purified by Protein-A/G affinity chromatography, by established procedures (2). Briefly, IgG from sera will be allowed to bind to Protein-A/G conjugated agarose beads in a chromatography column. After washing off all unbound serum proteins, Protein-A/G bound IgG will be eluted out by lowering pH to 2.5. Antibodies will stored in ⁇ 80° C.
- Antibody titer determination by ELISA Relative antibody titer will be determined by sandwich ELISA by a well-established protocol (17), and as described above. Briefly, ELISA plate will be coated with Peptide-1. Serial 10 fold dilutions of sera up to 100,000 will be used as a sample. After washing all unbound proteins from the plate, the amount of bound IgG specific to Peptide-1, will be determined by a secondary antibody, peroxidase-conjugated goat anti-horse IgG (17).
- purified antibody at a dose of 1 mg/kg body weight will be administered subcutaneously.
- the horse will be monitored for any abnormal reactions for 4 h continuously.
- the horse will be checked for pain and swelling at the site of injection. If the animal shows abnormal reactions such as sweating, high fever, cough, seizure or difficulty in breathing, it will be treated symptomatically. After 4 h, it will be observed once every hour until 8 h.
- the horse will be housed in the stall for 3 days. If everything is normal, the horse will be released back to the pasture. The remaining two horses will be treated and monitored similarly and released after 3 day if everything goes well. Blood (10 ml) will be collected weekly from each horse. Any horse reacting to the antibody will be treated with analgesics, corticosteroids and hot packs while in the stall.
- the remaining three horses will be given Peptide-1/KLH and adjuvant subcutaneously at a dose of 0.1 mg/kg, the same composition and dose used for foals as described above. In foals, this dose induced antibody production and did not produce severe reactions. Blood (10 ml) will be collected before the injection (for control value). After the peptide injection, 10 ml blood will be collected every 7 th day for the RAO season to determine antibody titer. Peptide injection will be performed in a stall, and the horses will be closely monitored for 3 days. If everything goes well with the horses, they will be released to the pasture. Their ability to resist RAO will be weekly observed during the period.
- the data will be analyzed for statistical difference between the groups and between the treated and untreated horse using a two-tailed repeated ANOVA for the titer values. If the significance is indicated, a post-hoc analysis will be performed using Tukey's test. Significance will be set at a “p” value of ⁇ 0.05 for all tests. It is expected that the horses given either Peptide-1 or its antibodies will have fewer symptoms and less severe symptoms of RAO during the RAO season.
- Guinea pigs a common animal model for human asthma, will be used. Guinea pigs will be vaccinated with Peptide-1 to see if Peptide-1 can help protect guinea pigs from getting asthma (experimentally induced asthma). This study will determine the antibody levels in guinea pigs injected twice (an initial injection and a 4-week booster injection) with Peptide-1 at a dose of 0.1 mg/kg subcutaneously, will determine the effectiveness of antibodies to Peptide-1 in protecting guinea pigs from experimentally induced asthma, and will determine the protection of guinea pigs from experimentally induced asthma by vaccination with Peptide-1.
- the second group of guinea pigs will be used for injecting antibodies to Peptide-1 at a dose of 1 mg/kg body weight. These animals will be observed for asthma signs. It is expected that the asthma signs from experimentally induced asthma will be reduced from the injection of the antibodies.
- the third group will be used to vaccinate with the peptide (first injection and booster injections). This group will be tested for protection from the experimental asthma as did with the second group.
- the animals will be sensitized by an intraperitoneal injection of ovalbumin at a dose of 100 mg/Kg body weight.
- the sensitized animals will be housed in separate cages and continuously observed for any clinical, physiological or behavioral alterations.
- the animals On the 10 th day after injection, the animals will be weighed.
- the animals will be challenged with ovalbumin at a lower dose of 100 ug/kg body weight (challenging dose) intraperitoneally (25).
- this challenging dose will cause an asthmatic response such as difficulty in breathing, increased effort to exhale air, gasping for air, rough coat, and curving of body.
- Peptide-1 can produce antibodies (active immunotherapy) or of antibodies to Peptide-1 (passive immunotherapy) can prevent guinea pigs from developing asthma signs, it will support the therapeutic use for asthma in mammals of the peptide or the antibody to the Peptide, including use in humans.
- Blood Collection Blood (2 ml) will be collected from jugular vein from guinea pigs sedated with barbiturates.
- Antibody extraction Total IgG antibody from hyper-immune sera collected from guinea pigs will be purified by Protein-A/G affinity chromatography, by established procedures (2). Briefly, IgG from sera will be allowed to bind to Protein-A/G conjugated agarose beads in a chromatography column. After washing off all unbound serum proteins, Protein-A/G bound IgG will be eluted out by lowering pH to 2.5. Antibodies will stored in ⁇ 80° C.
- Antibody titer determination by ELISA Relative antibody titer will be determined by sandwich ELISA by a previously described method (17), and as described above. Briefly, ELISA plate will be coated with peptide. Serial 10-fold dilutions of sera up to 100,000 will be used as sample. After washing all unbound proteins, the amount of bound IgG specific to the peptide, will be determined by a secondary antibody, peroxidase-conjugated goat anti-guinea pig IgG (17).
- the data will be analyzed for statistical difference between the experimental groups and the control group using a two-tailed repeated ANOVA for the titer values. If the significance is indicated, a post-hoc analysis will be performed using Tukey's test. Significance will be set at a “p” value of ⁇ 0.05 for all tests.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A peptide (Peptide-1) based on the C-terminal of Equine CC10 has been discovered that can be used as a vaccine to protect horses from respiratory airway obstruction (RAO), Antibodies to Peptide-1 may also be administered for short-term passive immunotherapy to RAO-affected horses, and can be used to measure the level of CC10 protein in serum to identify potential RAO horses (horses with reduced CC10). Due to similarities between equine RAO and human asthma, this peptide or its antibodies may also be useful in treatment or prevention of human asthma.
Description
- The benefit of the filing date of provisional U.S. application Ser. No. 61/494,948, filed 9 Jun. 2011, is claimed under 35 U.S.C. §119(e) in the United States, and is claimed under applicable treaties and conventions in all countries.
- This invention pertains to a unique peptide isolated from horse CC10 that can be used as a vaccine to protect horses from recurrent airway obstruction (RAO) and also to antibodies to this peptide which can be used in passive immunotherapy for short term protection against RAO or in assays to determine the level of CC10 protein in mammals. This new peptide can also be used to protect humans from asthma, based on the similarity between horse RAO and human asthma.
- Recurrent Airway Obstruction
- Recurrent Airway Obstruction (RAO), a respiratory disease similar to human asthma, is one of the most commonly diagnosed conditions affecting the lung of older horses all around world. It is a type-1 immediate hypersensitivity allergic disease involving a series of events that begin with reaginic antibodies, mainly IgE. These antibodies bind with high affinity to Fc epsilon-RI (FcεRI) receptors via the Fc portion that are found on the membrane of mast cells and basophils. Once bound, the antibodies can cross-link with environmental allergens, resulting in mast cell degranulation leading to the production of histamine and other chemical mediators that act together to induce airway inflammation. At least one reaginic antibody against Faenia rectivirgula, a common gram-positive bacteria, was found to be associated with lung diseases in RAO-affected and unaffected horses, finding the antibody present in about 15% in RAO-affected horses (28).
- Most evidence suggests that RAO is the result of a pulmonary hypersensitivity to inhaled antigens. Exposure of affected horses to hay dust, pollens, and mold spores leads to neutrophil accumulation in the lung and bronchospasm. The identification of allergen-specific IgE in bronchoalveolar lavage (BAL) fluid and sera of affected horses supports the involvement of a late phase, IgE-mediated, hypersensitivity reaction in the pathogenesis of equine RAO. The cytokine profiles of horse affected by RAO have been measured, and a modified Th2-like immune response was thought to be involved with elevated IL-4, IL-13 and IFNg levels (6,22).
- CC10 in RAO
- Clara Cell 10 kDa protein (CC10) is one of the members of a family of anti-inflammatory defense proteins produced predominantly in the airway epithelium of man and animals. In humans it is also called human uteroglobin (See U.S. Pat. Nos. 6,255,281 and 7,846,899). CC10 has been shown to inhibit the entry of eosinophils and neutrophils into the human airways during inflammation in the lung, and to inhibit enzymes that release inflammatory mediators (23). Some of the members of this family have been directly linked to protection from asthma, allergy and related inflammatory responses. The gene that encodes the protein was found to be down regulated during RAO in horses (34), and the production of the
CC 10 protein was also reported to be reduced in RAO horses (24). The amount of CC10 in the horse serum was measured using antibodies produced in rabbits using a synthetic 21 amino acid peptide from horse CC10 (EPSKPDADMKAATTQLKTLV; SEQ ID NO:2). This peptide corresponded to amino acids 47-66 of horse CC10 protein (protein accession no. NP 001075327.1) with two amino acid variations. - A hypo-allergic vaccine to an environmental antigen of Timothy grass pollen Profilins was developed by engineering its structure (35). The engineered protein was demonstrated to induce IgG's and inhibit allergic patients' IgE antibody binding to Profilins to a similar degree as those induced by immunization with the wild type. IgG's inhibited Profilin-induced basophil degranulation. Another environmental antigen, a novel Fel d1 cat allergy vaccine, was developed that induced strong IgG response, which abrogated the allergy response in mice (32). Allergen-induced systemic basophil degranulation was shown inhibited in an Fc gamma-RIIb-dependent manner (26). In addition, antibodies have been found in healthy horses; elevated IgG response were found in healthy horses to auto antigen (1). IgGb specific to KLH was found elevated in healthy versus control horses. An inverse correlation was reported between BCG vaccination and incidence of IgE mediated allergic diseases (18). BCG immunization was demonstrated to inhibit IgE production by B cells.
- Receptors for the Fc fragment of immunoglobulin-G (Fc gamma-R's) are important molecules not only to mediate and control the effectors' functions of IgG antibodies, but they also control the autoimmunity-tolerance balance in the periphery. In humans, three different types of Fc gamma-R's, belonging to the immunoglobulin gene super-family have been identified via Fc gamma-RI (CD64), Fc gamma-RII (CD32) and Fc gamma-RIII (CD16). In humans, myeloid cells express both activating and inhibitory receptors of the Fc gamma-RII family. Fc gamma-RIIA mediates processes associated with cell activation, while Fc gamma-RIIB down regulates such signaling. Differences in affinity for IgG between activating and inhibitory Fc gamma-R can result in substantial local changes in their relative concentrations with important functional consequences. Human airway smooth muscle cells express IgG-Fc gamma-RIIb with the potential to suppress remodeling and immune-modulation (36). A wide range of inflammatory and autoimmune diseases, such as vasculitis, glomerulonephritis, and autoimmune hemolytic anemia, seems to be mediated, in part, by Fc gamma-R's.
- Human Asthma and Animal Models
- Human asthma is a multifactorial disease, and is usually a chronic lung condition which can develop at any age and progress to a devastating disease. Asthma is classified as a hypersensitivity disease (5,30). An estimate shows that there are more than 150 million people with asthma worldwide, of which 20.3 million are in America. It is also important to note that the trend of deaths and hospitalization due to asthma is increasing in the industrialized countries of the world. Despite extensive research into the pathophysiology and treatment of asthma, high morbidity continues to threaten the human population. Because asthma can be induced by multiple stimuli, no single theory satisfactorily explains all types and cases, thus making a therapeutic regimen cumbersome.
- It is a well-established fact that the salient feature of human asthma is the tendency of the affected airways to overreact to a wide variety of nonspecific stimuli, which has led to the use of bronchial provocation tests as a method to diagnose the condition (19). This hyperreactivity is characterized by hyperresponsiveness and hypersensitivity of airways to various inflammatory mediators (13). This condition can result from abnormal tissue reaction in the airways either due to intrinsic stimuli arising from a biochemical, neurological, or humoral physiological imbalance in the body or due to extrinsic stimuli arising from the environment. The changes in the environment are detected in the airway mucosa by sensory receptors, which are richly innervated by sensory (afferent) fibers. Various respirable stimuli, including charged particles, allergens, irritants, as well as heat, cold and acid, activate sensory receptors.
- Animal models of human asthma: To examine various factors and mechanisms involved in pathogenesis of asthma, a number of mammalian animal models have been identified and used to study human airway hyperreactivity. For example, guinea pigs, which are not naturally susceptible to asthma, are used because of the ability to generate an experimentally-inducible model of asthma with indices similar to human asthma (14,15). Another animal model for asthma is mice which again are not naturally susceptible to asthma, but asthma can be induced experimentally. One advantage to mice is the ability to study the genetic aspects of the disease (12).
- Equine models of human asthma: A major advantage to an equine model is that horses get asthma naturally like people. Horses are important for the similarity between the signs and symptoms of recurrent airway obstruction (RAO) to those of asthma, for the similarity in the nature of disease progression to human asthma, and for the ability in horses to induce or precipitate an “asthmatic” episode (7,33). Histological findings such as thickening of epithelial basement membrane, edema, inflammatory infiltrate in bronchial walls, oversized submucosal glands, hypertrophy of bronchial wall muscle, and emphysematous changes are observed in both human asthma and in equine RAO (6,7,33). One difference is that the cellular infiltrate in RAO is mostly neutrophils, whereas esosinophils are more common with human asthma. Recently, identification of persistent nuclear factor kappa-B (NF-κB) activity in asthma and RAO clearly suggests that equine RAO is a better animal model of human asthma than those of other mammalian species (8,20). Chronic obstructive pulmonary disease (COPD) in horses, commonly called heaves, and currently termed recurrent airway obstruction (RAO), is an airway hyperreactivity disease comparable to human asthma (7,33). Horses with heaves spontaneously develop acute bronchiolitis after exposure to antigens such as hay or pasture mold. Heaves is a more common condition in temperate climatic regions where horses are confined in stables during winter seasons and where they are house near stored hay. Another form of RAO seen in the southern regions of the U.S. is summer pasture-associated obstructive pulmonary disease (SPAOPD), caused by allowing horses to graze on lush pasture in the humid summer months where molds and pollens in the grass serve as antigen stimulation (4). Both forms of RAO share common signs and symptoms (4,6,11). The clinically abnormal condition of RAO is characterized by hyperreactivity of airways to antigens, inflammatory mediators and various other external stimuli. The condition also presents a decreased dynamic compliance of lung and increased airflow resistance to histamine- or methacholine-challenges, which are the common tests performed for diagnosing either human asthma or equine RAO. When horses are exposed to diverse stimuli such as allergens or respirable irritants in the environment, their airways react with a specific response that includes infiltration of inflammatory cells in the lungs, damage of airway epithelium, and inflammatory mediator release. This reaction primes the airways to respond excessively to a broader range of stimuli. Continued stimulation leads to airway hyperreactivity, which is characterized by hypersensitivity (increased sensitivity of airway smooth muscles) and hyperresponsiveness (increased magnitude of smooth muscle contractility) to diverse stimuli as observed in human asthma (3,6,7,11). Thus, RAO in horses shares several common features of human asthma, such as airway hyperreactivity, severe bronchoconstriction, increased mucus production, presence of airway inflammatory mediators in bronchoalveolar lavage fluids, infiltration of inflammatory cells, difficulty in breathing and exercise intolerance. Horses then have several advantages as an animal model for human asthma. Of course, the main disadvantages to using horses are size and cost to obtain and house.
- U.S. Pat. Nos. 7,846,899 and 6,255,281 and U.S. Patent Application Publication No. 2005/0261180 describe the use of recombinant human CC10 (also referred to as human uteroglobin) and its use in various human inflammatory and respiratory disorders.
- U.S. Patent Application Publication No. 2011/0240012 describes the use of recombinant human CC10 and methods to administer CC10 nasally, and its use in treatment of various nasal inflammatory diseases, including rhinitis and sinusitis.
- We have discovered a 21 amino acid (aa) peptide (Peptide-1; SEQ ID NO: 1; KNTKDSILKLMDKIAKSPLCA) based on the C-terminal of Equine CC10 that can be used as a vaccine to protect horses from RAO, and protect humans from asthma. We have produced a rabbit polyclonal antibody to this peptide, and validated the specificity of antibody by ELISA. We tested the sera of healthy and RAO affected horses for CC10 using this antibody in a competitive inhibition ELISA, and surprisingly found that sera from some of the healthy horses showed significantly higher titers than the maximum titer expected with the control. This result could only be explained if horse sera itself had antibodies to Peptide-1, suggesting that healthy horses are protected from RAO by antibodies similar to the polyclonal antibodies produced by Peptide-1. We believe that such auto-antibodies may be the result of exposure to environmental allergens that have ‘molecular mimicry’ to the sequence of Peptide-1. To confirm this belief, we performed a sequence analysis using the BLAST algorithm and found that several known natural antigens have a similar sequence to Peptide-1. We have identified a unique isolated peptide sequence (Peptide-1) which can be used as a vaccine for protection of horses from RAO and seasonal allergy. The advantages to Peptide-1 are: (1) it may be used in young animals as a vaccine to protect them from RAO later in life; (2) antibodies to Peptide-1 may be administered for short-term passive immunotherapy to RAO-affected horses; and (3) antibodies to Peptide-1 can be used in measuring the level of CC10 protein in animals to identify potential RAO horses (horses with reduced CC10). In addition due to the homology with the human protein CC10 and since human seasonal allergy (or asthma) has the same mechanism of induction as horse RAO, we believe that this Peptide-1 or homologous sequences or its antibodies may be useful therapeutically in humans for protection against or alleviating the symptoms of asthma.
-
FIG. 1 illustrates the results of an antibody capture endpoint ELISA showing the Peptide-1 specific antibody titer with Peptide-1 as the capture antigen, peroxidase-conjugated goat anti-rabbit IgG as the detection antibody, and the isolated rabbit antibody at several dilutions. -
FIG. 2 illustrates the results of a competitive inhibition ELISA assay using a series of concentrations of Peptide-1. -
FIG. 3 illustrates the amount of CC10 IgG titer from five healthy horses (without RAO) as compared to the control as measured using competitive inhibition ELISA assay. -
FIG. 4 illustrates the amount of Peptide-1 specific IgG titer using a direct sandwich ELISA and measuring serum from eight healthy horses standardizing the value by subtracting the control value of UGRP peptide from the experimental values for CC10. -
FIG. 5A illustrates the amount of Peptide-1 specific IgG titer in serum fromFoal # 2 primed onday 0 and boosted on day 29 by subcutaneous injection of 0.1 mg/kg Peptide-1. Antibody titer determined using a direct sandwich end point ELISA with Peptide-1 as a capture antigen and peroxidase conjugated goat anti-equine IgG as a detection antibody. -
FIG. 5B illustrates the amount of Peptide-1 specific IgG titer in serum fromFoal # 3 primed onday 0 and boosted on day 29 by subcutaneous injection of 0.1 mg/kg Peptide-1. Antibody titer determined using a direct sandwich end point ELISA with Peptide-1 as a capture antigen and peroxidase conjugated goat anti-equine IgG as a detection antibody. - The term “Peptide-1” refers to a 21 amino acid (aa) peptide (Peptide-1; SEQ ID NO: 1; KNTKDSILKLMDKIAKSPLCA) based on the C-terminal of Equine CC10 that can be used as a vaccine to protect mammals from a respiratory airway disorder. This invention relates not only to a functional Peptide-1 as described in this specification, but also to peptides having modifications to such a sequence resulting in an amino acid sequence having the same function (i.e., the ability to be used as a vaccine for protection against antigen-caused respiratory disorders), and about 80%, preferably 85%, and more preferably 90% homology to the sequence of the amino acid sequence as described, and most preferably about 95% or greater homology, particularly in conserved regions. “Homology” as used here means identical amino acids or conservative substitutions (e.g., acidic for acidic, basic for basic, polar for polar, nonpolar for nonpolar, aromatic for aromatic). The degree of homology can be determined by simple alignment based on programs known in the art, such as, for example, GAP and PILEUP by GCG, or the BLAST software available through the NIH interne site. Most preferably, a certain percentage of “homology” would be that percentage of identical amino acids.
- The term “vaccine” refers to a composition or compound (an antigen) used to stimulate an immune response in a mammal and so confer resistance to the disease or infection in that mammal, including an ability of the immune system to remember the previously encountered antigen. Antibodies are produced as a result of the first exposure to an antigen and stored in the event of subsequent exposure.
- The term “adjuvant” refers to non-antigenic substance that, in combination with an antigen, enhances antibody production by inducing an inflammatory or other non-defined response, which leads to a local influx of antibody-forming cells. Adjuvants are used therapeutically in the preparation of vaccines, since they increase the production of antibodies against small quantities of antigen, lengthen the period of antibody production, and tend to induce memory cell responses. Such adjuvants could include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, aluminium hydroxide, dimethyldioctadecylammonium bromide, Adjuvax (Alpha-Beta Technology), Imject Alum (Pierce), Monophosphoryl Lipid A (Ribi Immunochem Research), MPL+TDM (Ribi Immunochem Research), Titermax (CytRx), toxins, toxoids, glycoproteins, lipids, glycolipids, bacterial cell walls, subunits (bacterial or viral), carbohydrate moieties (mono-, di-, tri- tetra-, oligo- and polysaccharide) various liposome formulations or saponins. Alum is the adjuvant currently in use for human patients. However, for horses, incomplete Freund's adjuvant may be used.
- The term “immune response” refers to the reaction of the body to an antigen, which is usually a foreign or potentially dangerous substances (antigens), particularly disease-producing microorganisms. However, in the current technology, a new peptide sequence that is similar to an endogenously produced defense protein (CC10) is used for the antigen. The response involves the production by specialized white blood cells (lymphocytes) of proteins known as antibodies, which react with the antigens to render them harmless. The antibody-antigen reaction is highly specific. Vaccines also stimulate immune responses.
- The term “immunologically effective amount” refers to the quantity of an immune response inducing substance required to induce the necessary immunological memory required for an effective vaccine. For example, Peptide-1 at a dose of 0.1 mg/kg body weight when given subcutaneously has been found an immunologically effective amount.
- The pharmaceutical compositions of the present invention are advantageously administered in the form of injectable compositions. A typical composition for such purpose comprises a pharmaceutically acceptable carrier. For instance, the composition may contain human serum albumin in a phosphate buffer containing NaCl. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like (REMINGTON'S PHARMACEUTICAL SCIENCES, 15th Ed., Easton ed., Mack Publishing Co., pp 1405-1412 and 1461-1487 (1975) and THE NATIONAL FORMULARY XIV, 14th Ed., American Pharmaceutical Association, Washington, D.C. (1975), both hereby incorporated by reference). Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyloleate. Aqueous carriers include water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, etc. Intravenous vehicles include fluid and nutrient replenishers. The pH and exact concentration of the various components the pharmaceutical composition are adjusted according to routine skills in the art. Goodman and Gilman, THE PHARMACOLOGICAL BASIS FOR THERAPEUTICS (7th ed.).
- In addition for a small peptide, the peptide may be covalently linked to an immunogenic protein carrier to increase its recognition by the immune system as foreign. Common protein carriers include keyhole limpet hemocyanin (KLH). Bovine serum albumin (BSA), chicken egg albumin (OVA), and immunoglublin Fc fragment. Recently, non-proteinic nanoparticles have been used as carriers.
- Typically, such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation also may be emulsified. The active immunogenic ingredient is often mixed with an excipient that is pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH-buffering agents, adjuvants or immunopotentiators that enhance the effectiveness of the vaccine.
- The vaccines are conventionally administered intraperitoneally, intramuscularly, intradermally, subcutaneously, orally, nasally, or parenterally. Additional formulations are suitable for other modes of administration and include oral formulations. Oral formulations include such typical excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. Additionally, the peptide can be encapsulated in a sustained release formulations or a coating that resist the acidic pH of the stomach. The compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25-70%. In a preferred solution, equal volumes of Peptide-1 conjugated with KLH and Incomplete Freund's adjuvant were used in a subcutaneous injection. Other possible routes of administration is to use a DNA expression vector with a nucleic acid sequence encoding the Peptide 1 (SEQ ID NO:1) for immunization using intradermal or intramuscular techniques.
- The dose to be administered depends on a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent, i.e., carrier or vehicle, and a particular treatment regimen. The quantity to be administered, both according to number of treatments and amount, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and degree of protection desired. The precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosage ranges are on the order of one to several hundred micrograms of active ingredient per individual subject. Suitable regimes for initial administration and booster shots also vary but are typified by an initial administration followed in one or two week intervals by one or more subsequent injections or other administration. Annual boosters may be used for continued protection.
- An isolated 21-amino acid peptide was designed and made based on the ‘C’ terminal 21 amino acid peptide of Equine CC10 protein (Accession no. NP_001075327.1) (“Peptide-1; SEQ ID NO:1; KNTKDSILKLMDKIAKSPLCA). The sequence of this peptide corresponds to amino acids 71-91 of equine CC10 and does not overlap with that of the peptide (amino acids 47-66) previously used to make rabbit antibodies (24). Peptide-1 was used to develop rabbit polyclonal antibodies. Briefly, Peptide-1 was conjugated to the carrier protein KLH (Keyhole Limpet Hemocyanin), and the conjugate used to immunize naïve rabbits to induce an immune response. Antibodies were purified from serum of immunized rabbits by established chromatographic techniques as described previously (21). The rabbit antibody was verified in an antibody capture endpoint Enzyme-Linked ImmunoSorbent Assay (ELISA) with Peptide-1 as the capture antigen and peroxidase conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa.) as the detection antibody as described previously (9). As shown in
FIG. 1 , the rabbit antibody had a titer of >100,000 with an optimum detection range between 1000 and 10,000 dilutions (FIG. 1 ). - Development of a Competitive Inhibition ELISA Assay
- Based on the results in
FIG. 1 , a 1:5000 dilution of this antibody was used for further CC10 detection in a competitive ELISA. To validate the competitive inhibition assay, a series of Peptide-1 dilutions starting at 1000 μg/mL was prepared. From each dilution, 50 μL was mixed with 50 μL of a solution of 1:5000 diluted rabbit polyclonal antibody. This mixture was incubated for 30 min, and then used in ELISA with a Peptide-1 coated plate as described previously (9). As shown inFIG. 2 , the inhibition of antibody binding to peptide coated plated was dependent on Peptide-1 concentration. - Determination of CC10 Specific IgG Titer—Elevated CC10 IgG Titer
- The competitive ELISA system as described above (Example 2) was used to measure relative levels of CC10 in the serum of 5 healthy and 5 RAO horses. Briefly, 10 μL of serum from each horse was mixed with 50 μL of a 1:5000 diluted rabbit antibody to Peptide-1 and incubated at 37° C. for 30 min. This serum-antibody mixture was then added to wells on ELISA plate pre-coated with Peptide-1 and blocked with 2% milk powder proteins (Carnation Milk, Nestle). The amount of free peptide specific rabbit antibody available to bind to Peptide-1 coated on the plate varied, depending on the amount of
native CC 10 present in the scrum sample. Plates were washed, and the amount of rabbit IgG bound to the plate was measured using Goat anti-rabbit IgG-HRP (Jackson ImmunoResearch Laboratories, Inc.). Surprisingly, some of the healthy horses had a significantly high titer than the control samples which had only rabbit peptide IgG without the addition of any horse sera. InFIG. 3 , the absorbance titer data for healthy horses was normalized to that of control as 100%. Two of the five healthy horses, or 40%, showed significantly increased titer for CC10 in sera over that of the controls. - The titer levels were too significant to consider the levels as resulting from non-specific binding of IgG present in horse serum. Without wishing to be bound by this theory, we believe that at least some healthy horses have significant IgG antibody levels already that would bind to the 21 amino acid peptide (Peptide-1) of CC10. The goat anti-IgG to rabbit was used for detection, and it is a pan specific antibody that is cross-reactive across many species including horse IgG. Such auto-antibodies in the horse serum may be produced due to exposure to environmental allergens that show ‘molecular mimicry’ to the sequence of Peptide-1. As described below, a sequence analysis using the BLAST algorithm as previously described (9) was conducted, and found that several known antigens in nature have a similar sequence to Peptide-1.
- BLAST Sequence Homology Analysis—Homology to Microbial Antigens, Molecular Mimicry
- The Peptide-1 sequence was used in a protein BLAST sequence analysis against published bacterial and fungal proteins. High homology to some bacterial and fungal proteins including to Aspergillus, a known environmental allergen was found. (Table 1).
-
TABLE 1 No. Protein ID Species % Identity 1. Q65R19_MANSM Mannheimia 90% AspA Protein succiniciproducens (Bovine rumen bacteria) 2. D3V5R2_XENBV Xenorhabdus bovienii 71% (bacteria found in nematodes) 3. C4VBG4_NOSCE Nosema ceranae 58% (microsporidium usually affecting bees) 4. A2R1F5_ASPNC Aspergillus niger 61% (common soil and plant fungus) - BLAST searches using the whole horse CC10 was also conducted and found significant homology to a cat
allergen Fel d 1 and to a putative U1p1 protease protein in Aspergillus fumigatus (Table 2). -
TABLE 2 No. Protein ID Species % Identity 1. P30438.2 Fel d1 Felis catus 37% (domestic cat) 2. NC_007 198.1 Aspergillus fumigatus 51% U1 p1 protease (fungus commonly found in soil) - Elevated Peptide-1 Specific IgG in Healthy Horses
- To further validate if an elevated CC10 specific IgG antibody titer existed in healthy horses, sera from eight healthy horses with no sign of RAO were collected. To determine levels of Peptide-1 specific IgG titer, a direct sandwich ELISA was used according to published protocols (18). Diluted healthy horse serum samples were added to a plate coated with Peptide-1. The peptide bound horse IgG antibody was then detected using peroxidase conjugated goat anti horse IgG antibody (Jackson ImmunoResearch Laboratories, Inc.). As control, a 17 amino acid ‘C’ terminal peptide from UGRP1 protein (another member of the CC10 family) was used. As shown in
FIG. 4 , elevated amounts of antibodies to Peptide-1 was again found in healthy horses. This result further supported that Peptide-1 specific IgG is present in many healthy horses (FIG. 4 ). - These results confirm that elevated levels of Peptide-1 specific antibodies are found in healthy horses. Without wishing to be bound by this theory, we believe that this elevated level is due to molecular mimicry. Homology of a self-protein to a microbial protein can induce antibody response to the self-antigen if exposed to the microbial or fungal product early in life. Sequence analysis as shown above indicated a high homology of Peptide-1 to some microbial and fungal proteins including Aspergillus, a known environmental allergen. It is possible that augmented immune responses generated in these healthy horses early in life afforded them protection subsequently in life.
- The hygiene hypothesis suggests that a reduced frequency of infections, less severe infection, and prevention of infection (for example, by a frequent use of antibiotics) would prevent maturation of Th-1 immunity and, therefore, would give rise to an allergen-specific Th-2 immune response following natural exposure to allergens. The immunological explanation for the “hygiene hypothesis” has been proposed to be the induction of T helper 1 (Th1) responses by microbial products. However, the protective results of hygiene hypothesis-linked microbial exposures are currently shown to be unlikely to result from a Th1-skewed response. The hygiene hypothesis has been proposed to be more important in regulating the PMN-dominant inflammatory response than in inducing a Th1-dominant response (10). Endotoxins, part of the outer membrane of Gram negative bacteria, are a potent inducer of neutrophilic airway inflammation. The risk of non-atopic asthma, characterized by neutrophilic response, is enhanced in subjects with higher endotoxin exposure. This information is in accordance with the so-called hygiene hypothesis and have been supported by animal studies and at the cellular level (11). Thus vaccinating the horses at a young age with Peptide-1 will produce protective immune response which will protect them from environmental allergens.
- Auto-antibodies to equine CC10 ‘C’ terminal 21 amino acid peptide (Peptide-1) were observed in horses resistant to RAO. Sequence analysis showed some homology of Peptide-1 to several bacterial and fungal sequences. Therefore, it is possible that the antibodies were developed due to molecular mimicry to microbial antigens. Activation of B-cells carrying Fc gamma-RII receptor by these autoantibodies may be protective, while activation of Fc∈R1 receptor induces disease. Immunization of horses with Peptide-1 early in life can provide protection from RAO later in life.
- Peptide-1 can be used as a vaccine for young horses to protect them from developing the respiratory allergy later in their life. In addition, the antibody produced to Peptide-1 can be used in passive immunotherapy for short term therapy to decrease the symptoms of a horse or other mammal with respiratory airway disease. Antibodies to Peptide-1 can also be used to determine the level of CC10 protein in horses. A decreased level of CC10 in the serum could be a biomarker for detecting horses that are vulnerable to RAO which will facilitate early selection and improved breeding. In addition, Peptide-1 or similar peptide may also be useful in developing a vaccine to protect people that are susceptible to allergic diseases such as human asthma.
- Vaccination of Foals with Peptide-1
- A pilot study in foals was started in January 2012 to determine whether an immune response could be generated by vaccinating foals with Peptide-1, a newly identified peptide from Clara Cell proteins of horses. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of Louisiana State University to be conducted in nine Shetland foals. The foals were obtained from the Equine Health Studies Program of the LSU School of Veterinary Medicine, Baton Rouge, La. 70803. They ranged in age from 4 to about 6 months. This study is still continuing. So far Peptide-1 has been injected into 3 foals, but all nine foals will be injected in a manner similar to that described below. The body weights of the three foals injected ranged from about 101 to about 112 kg.
- The foals were selected based on a thorough physical examination by a board certified equine clinician and a complete blood count (CBC) was performed to determine any clinical pathology. Since Peptide-1 is a small peptide, it was covalently conjugated with a large carrier protein, Keyhole Limpet Hemocyanin (KLH), for easy recognition by the lymphocytes to produce antibody production. KLH is a commonly used as a carrier protein.
- Two days before the injection of the peptide-1, a foal along with the mare was brought from the pasture to a bedded stall of the LSU School of Veterinary Medicine. They were fed hay and concentrated horse chow (
Horse Chow # 200R, Purina Mills, St. Louis, Mo.); water was provided ad libitum. A physical examination was conducted on the day of injection. The foal's body temperature, heart rate, respiratory rate, body weight, body score, sex, breed, age and general physical conditions were recorded. After the physical examination, 5 ml of blood was drawn from jugular vein to determine pre-immune antibody titer (control value) and CBC. - Foal #1:
- Since the peptide-1 has not been tried in any animals, the first foal was used to test the injection method and dosage. A low dose of 0.1 mg/kg body weight of conjugated peptide-1 with KLH was used, but without an adjuvant to minimize any adverse reactions due to either a high dose of peptide-1 or adjuvant. This protocol allowed a determination of any reaction due to the conjugated peptide-1 alone. A subcutaneous route of administration was chosen to produce a consistent “slow and steady” absorption. The first injection was given on the left side of the neck after cleaning with alcohol. No major adverse reaction was observed at the site of injection or on the animal as a whole. A small swelling was observed at the site of injection which disappeared after two days. The foal did not have any fever or any other clinical pathological changes. After the injection, 5 ml blood was collected weekly. A booster injection with the same dose and route was given on the right side of the neck on the 15th day following the initial injection. Weekly blood collections continued for 42 days. The antibody titer did not change from the pre-immune values in this foal (Data not shown). For the remaining foals, a new protocol was used in that an adjuvant was added to the injection and the booster injection was given on the 28th day after the initial injection.
-
Foal # 2 - The same protocol as described above for
Foal # 1 was used in this foal except for the addition of the adjuvant and a change in booster injection time. An equal volume of Incomplete Freund's Adjuvant (IFA; Sigma Chemicals, St. Louis, Mo.) and Peptide-1 was mixed well and administered subcutaneously. The total volume of injection did not exceed 2 ml, and the does of Peptide-1 remained as inFoal # 1. Prior to the first injection and weekly thereafter, 5 ml blood was drawn for analysis. A booster injection of adjuvant/Peptide-1 was given on the 28th day following the initial injection. - Immediately after injection (either the first injection or the booster), a small swelling (
size 1″×0.5″) at the site of injection was observed. The foal was observed continuously for the first hour and later every hour for eight hours. The foal evinced pain upon touch at the injection site, but it was eating, nursing, and drinking within 15 minutes after injection. The foal showed no other adverse reaction, and it was bright, alert and responsive. No sweating, fever, cough, seizure or difficulty in breathing was observed. - By the end of 24 h, the swelling at the injection site had spread to an area of 2.5″×2″ size, and had a thickness of only 0.5″. The foal remained under close observation for another two days, when the swelling began to subside. On the third day, foal and mare were allowed to go to the pasture. A similar swelling occurred at the booster injection time also. Therefore, in the animal protocol, foals would be kept in the bedded stall with the mare for a week after injection to observe the foals closely. In addition, the protocol demanded that if the swollen area is more than 2.5″ in diameter and more than 0.5″ in thickness, hot water packs are to be applied to relieve pain and swelling. Veterinary medical care is to be consulted if the condition worsens. After one week in the stall, the
Foal # 2 was let out to pasture and continued to do well for the remainder of the experimental period of 57 days. - The peptide-1 specific total IgG antibody titers were determined in the serum samples by enzyme labeled immune sorbent assay (ELISA). So far, eight samples have been tested in this foal for a time period of 57 days. The results are shown in
FIG. 5A . The samples were taken on pre-injection serum collected onday 0, and then every seven days thereafter. The results indicate that the antibody titer to Peptide-1 increased exponentially after day 15 up to day 22, when there was a drop. After the booster on day 29, the antibody titer increased to a peak level at day 36, but remained at elevated levels for the remaining period. As shown inFIG. 5A , Peptide-1 at a dose of 0.1 mg/kg when injected subcutaneously with an adjuvant can produce significant amounts of antibodies. We believe that this increase in antibodies to Peptide-1 will immunize these young horses and protect them from recurrent airway obstruction (RAO). We also believe that the purified antibodies produced in the foal can be isolated and given to adult horses to protect horses with a history of RAO (susceptible horses). -
Foal # 3 - The basic protocol is as described for
Foal # 2. However, before injecting the peptide, extra care was taken in cleaning the injection site by scrubbing the site with Septisol antiseptic foam (SeptisolR, Steris Corp., Ohio) and alcohol. This additional step reduced the swelling considerably over what was seen inFoal # 2. There was a small swelling in this foal which lasted only for 24 hours, probably due to the adjuvant. The adjuvant has an oily consistency, which would facilitate slow absorption of the injected solution. -
Foal # 3 is still being followed. The results to date are shown inFIG. 5B . As shown inFIG. 5B , the antibody titer did not increase until about day 15, similar toFoal # 2. It then peaked on day 22, and then again after the booster on day 29. The response curve for this foal closely follows the response curve ofFoal # 2, confirming the effectiveness of Peptide-1 in producing antibodies. - Future Studies in Foals
- Thus far, only a single dose and route have been tried. In future studies with foals, a lower (0.03 mg/kg) and a higher dose (0.3 mg/kg) of the peptide-1 will be tried to show what difference in response can be expected with one log dose difference. Administration of a higher dose and observation of the foal for adverse reactions will also demonstrate if any toxicity exists with the peptide. With large animals such as horses, determination of LD50 (lethal dose for 50% of the animals tested) is not usually performed. In addition, a nasal route of administering Peptide-1 will be tried because of its convenience to use.
- Use of Peptide-1 or its Antibodies to Protect Adult Horses
- Peptide-1 will be used to vaccinate adult horses, or antibodies to Peptide-1 will be used for short term protection for adult horses. Initial experiments will determine the effectiveness of use of the peptide or its antibody to protect adult horses from recurrent airway obstruction (RAO). Experiments to achieve the following three objectives will be conducted: (1) a determination of the antibody levels in horses that receive two subcutaneous injections of the peptide one month apart; (2) a determination of whether the horses can maintain a sufficient titer of antibody for immunity from an injection given during the remission period; and (3) a determination of whether horses that receive the peptide injection or an injection of antibodies are resistant to RAO or develop lesser symptoms of RAO.
- Following approval from the IACUC, this study will be performed in 6 horses that are known to be susceptible to RAO (3 for injection of Peptide-1 (the “active immunity” group), and 3 for injection of antibodies (the “immunotherapy” group)). Horses with a history of RAO will be obtained by donation to the LSU School of Veterinary Medicine. Susceptibility to RAO in the horses will be determined on the basis of their history of the disease, physical examination, clinical scoring based on signs of RAO, pulmonary function testing (determining transpleural pressure (Ppl)), and bronchoalveolar (BAL) fluid examination. None of the horses will have received medications within 10 days prior to the assessment. Three horses will be injected with the peptide, and 3 will be injected with antibody to Peptide-1. The antibodies will be extracted from the blood of foals that were injected with Peptide-1 as described above. A onetime collection of blood of 450 ml from each foal will be collected. If adult horses, as expected, maintain high antibody titer values after injection of Peptide-1, antibody from the adult horses can also be used. The sera with high antibody titers value will be pooled for purification and antibody extraction.
- Techniques for Selection of Horses, Antibody Titer Determination & Antibody Extraction.
- Transpleural pressure determination: The change in transpleural pressure (Ppl) will be measured indirectly as previously described (31,34). Briefly, a 10-cm long 3.5-cm circumference esophageal balloon will be secured at one end of a catheter (PE tubing 350). The catheter will be connected to a pressure transducer (model PESO) interfaced with a polygraph (Grass model 7D). The balloon will be inserted through a lubricated nasogastric tube (bigger tube) placed in the rostral esophagus. Once the balloon is located between the heart and the diaphragm, the nasogastric tube will be removed. The balloon will be inflated with 1.5 ml of water, and 10 measurements will be recorded. Changes in esophageal pressure (peak inspiratory pressure minus peak expiratory pressure) during tidal breathing will reflect the change in Ppl (measures as cm H2O). Horses with a Ppl of about 15 or greater will be selected for the study. This measurement will help confirm the horse has RAO and will get episodes of the disease seasonally.
- Bronchoalveolar lavage (BAL) fluid collection: Horses will be sedated using a combination of xylazine hydrochloride (0.5 mg/kg, given intravenously (IV)) and butorphanol tartarate (11 mg/kg, IV). After placement of a nose twitch, a 244-cm (11-mm outer diameter, 3-mm inner diameter) flexible silicone tube will be passed through the nasal passage into the trachea to wedge in the distal airway. As the silicone tube is advanced through the trachea and carina, 36 mL of 1% lidocaine will be injected through the tube and followed by 30 mL of air. The cuff will be inflated with 4 mL of air, and five 60-mL aliquots of sterile 0.9% saline will be infused manually with 60 mL syringes. Immediately after infusion, bronchoalveolar lavage fluid (BALF) will be collected and pooled into a sterile flask. Cytological analysis of BAL fluid will demonstrate whether the horses have any other respiratory problem (10,31)
- Clinical Scoring: The horses will be assigned a clinical score (CS). The CS is determined by the following algorithm (31, 34.
-
- Each of these variables in the formula is scored from 0 to 4. The zero score indicates the nostril has little movement, and the ventral flank shows little or no movement. A score of 4 indicates the nostril remains maximally flared throughout the respiratory cycle and abdominal lift resulting in a “heave line” extending cranially to the 5th intercostal space. Thus, the maximum CS is 8. Clinically healthy horses will have clinical scores <4.0. RAO horses will have a score of >5.0. This non-invasive procedure will show whether the animal has RAO.
- Blood Collection: Foals that have previously injected with Peptide-1 will be used to supply antibodies to Peptide-1 as discussed above. A one-time sample of 450 ml blood will be collected from each foal, all of whom are currently above 200 lb body weight. For adult horses, 10 ml blood will be collected from the adult horses before the injection (peptide or antibody) and weekly thereafter until the season (June, July, August) is over.
- Antibody extraction: Total IgG antibody from hyper-immune sera collected from foals will be purified by Protein-A/G affinity chromatography, by established procedures (2). Briefly, IgG from sera will be allowed to bind to Protein-A/G conjugated agarose beads in a chromatography column. After washing off all unbound serum proteins, Protein-A/G bound IgG will be eluted out by lowering pH to 2.5. Antibodies will stored in −80° C.
- Antibody titer determination by ELISA: Relative antibody titer will be determined by sandwich ELISA by a well-established protocol (17), and as described above. Briefly, ELISA plate will be coated with Peptide-1. Serial 10 fold dilutions of sera up to 100,000 will be used as a sample. After washing all unbound proteins from the plate, the amount of bound IgG specific to Peptide-1, will be determined by a secondary antibody, peroxidase-conjugated goat anti-horse IgG (17).
- Experimental Protocol: Eight adult horses that have a history of RAO will be clinically scored and pulmonary function tested during the active RAO period (June, July, August & may be September). This will confirm their susceptibility to RAO. The horses will remain in the pasture for the complete RAO season. After the RAO season, the horses will begin to undergo remission, and by November, will not show active signs of RAO. Without treatment, the RAO will return in the next RAO season, starting in June. This initial season of monitoring will allow each horse to be used as its own control.
- One month before the beginning of the second RAO season, 3 horses will be given antibodies at a dose of 1 mg/kg body weight subcutaneously. A day before the injection, a horse will be brought to a bedded stall. The horse will be fed hay and concentrates; and water will be given ad libitum. A 10-ml blood sample will be drawn for determining CBC and antibody titer. A thorough physical examination including body temperature, heart rate, respiratory rate, body weight, body score, sex, breed age and general physical conditions will be recorded.
- The following day, purified antibody at a dose of 1 mg/kg body weight will be administered subcutaneously. The horse will be monitored for any abnormal reactions for 4 h continuously. The horse will be checked for pain and swelling at the site of injection. If the animal shows abnormal reactions such as sweating, high fever, cough, seizure or difficulty in breathing, it will be treated symptomatically. After 4 h, it will be observed once every hour until 8 h. The horse will be housed in the stall for 3 days. If everything is normal, the horse will be released back to the pasture. The remaining two horses will be treated and monitored similarly and released after 3 day if everything goes well. Blood (10 ml) will be collected weekly from each horse. Any horse reacting to the antibody will be treated with analgesics, corticosteroids and hot packs while in the stall.
- The remaining three horses will be given Peptide-1/KLH and adjuvant subcutaneously at a dose of 0.1 mg/kg, the same composition and dose used for foals as described above. In foals, this dose induced antibody production and did not produce severe reactions. Blood (10 ml) will be collected before the injection (for control value). After the peptide injection, 10 ml blood will be collected every 7th day for the RAO season to determine antibody titer. Peptide injection will be performed in a stall, and the horses will be closely monitored for 3 days. If everything goes well with the horses, they will be released to the pasture. Their ability to resist RAO will be weekly observed during the period.
- Analysis of results: The data will be analyzed for statistical difference between the groups and between the treated and untreated horse using a two-tailed repeated ANOVA for the titer values. If the significance is indicated, a post-hoc analysis will be performed using Tukey's test. Significance will be set at a “p” value of <0.05 for all tests. It is expected that the horses given either Peptide-1 or its antibodies will have fewer symptoms and less severe symptoms of RAO during the RAO season.
- Vaccination of Guinea Pigs with Peptide-1
- We believe that other mammals can be treated with Peptide-1 or its antibodies to decrease the symptoms of asthma, including humans. Guinea pigs, a common animal model for human asthma, will be used. Guinea pigs will be vaccinated with Peptide-1 to see if Peptide-1 can help protect guinea pigs from getting asthma (experimentally induced asthma). This study will determine the antibody levels in guinea pigs injected twice (an initial injection and a 4-week booster injection) with Peptide-1 at a dose of 0.1 mg/kg subcutaneously, will determine the effectiveness of antibodies to Peptide-1 in protecting guinea pigs from experimentally induced asthma, and will determine the protection of guinea pigs from experimentally induced asthma by vaccination with Peptide-1.
- Description of Investigation: Following approval from the IACUC, this study will be performed in 3 groups of healthy guinea pigs (10 guinea pigs in each group). In
group # 1, guinea pigs will be injected with Peptide-1/KLH and adjuvant initially and then again 4 weeks later (the booster injection. Blood (2 ml) will be drawn from the jugular vein to determine antibody titer. Blood samples will be collected before the initial injection of the peptide, and then once every week for two months. The blood samples will be used to determine the level of antibody titer. If the guinea pigs have sufficient level of antibody, they will be used for antibody extraction. - The second group of guinea pigs will be used for injecting antibodies to Peptide-1 at a dose of 1 mg/kg body weight. These animals will be observed for asthma signs. It is expected that the asthma signs from experimentally induced asthma will be reduced from the injection of the antibodies. The third group will be used to vaccinate with the peptide (first injection and booster injections). This group will be tested for protection from the experimental asthma as did with the second group.
- Experimental Induction of asthma: Asthma will be induced in guinea pigs by a method previously described (16). Healthy Guinea pigs will be procured from a USDA licensed dealer and housed in a regulated animal facility. Animals will be weighed and prepared for sterile injection of ovalbumin. Blood (2 ml) will be collected from the jugular vein.
- The animals will be sensitized by an intraperitoneal injection of ovalbumin at a dose of 100 mg/Kg body weight. The sensitized animals will be housed in separate cages and continuously observed for any clinical, physiological or behavioral alterations. On the 10th day after injection, the animals will be weighed. Then the animals will be challenged with ovalbumin at a lower dose of 100 ug/kg body weight (challenging dose) intraperitoneally (25). In sensitized animals, this challenging dose will cause an asthmatic response such as difficulty in breathing, increased effort to exhale air, gasping for air, rough coat, and curving of body. If administration of Peptide-1 can produce antibodies (active immunotherapy) or of antibodies to Peptide-1 (passive immunotherapy) can prevent guinea pigs from developing asthma signs, it will support the therapeutic use for asthma in mammals of the peptide or the antibody to the Peptide, including use in humans.
- Blood Collection: Blood (2 ml) will be collected from jugular vein from guinea pigs sedated with barbiturates.
- Antibody extraction: Total IgG antibody from hyper-immune sera collected from guinea pigs will be purified by Protein-A/G affinity chromatography, by established procedures (2). Briefly, IgG from sera will be allowed to bind to Protein-A/G conjugated agarose beads in a chromatography column. After washing off all unbound serum proteins, Protein-A/G bound IgG will be eluted out by lowering pH to 2.5. Antibodies will stored in −80° C.
- Antibody titer determination by ELISA: Relative antibody titer will be determined by sandwich ELISA by a previously described method (17), and as described above. Briefly, ELISA plate will be coated with peptide. Serial 10-fold dilutions of sera up to 100,000 will be used as sample. After washing all unbound proteins, the amount of bound IgG specific to the peptide, will be determined by a secondary antibody, peroxidase-conjugated goat anti-guinea pig IgG (17).
- Analysis of results: The data will be analyzed for statistical difference between the experimental groups and the control group using a two-tailed repeated ANOVA for the titer values. If the significance is indicated, a post-hoc analysis will be performed using Tukey's test. Significance will be set at a “p” value of <0.05 for all tests.
-
- 1. Ainsworth D. M., Appleton J. A., Antczak D. F., Santiago M. A., Aviza G. IgG antibody responses to an inhaled antigen in horses with “heaves” (recurrent airway obstruction). Vet Immunol. Immunopathol. 84(3-4):169-80 (2002 Jan. 15).
- 2. Akerstrom B., Bjorck L. (1986) A physicochemical study of protein G, a molecule with unique immunoglobulin G-binding properties. J. Biol. Chem. 261:10240-7.
- 3. Barnes P. J., Chung K. F., Page C. P. Inflammatory mediators of asthma. Pharmacol. Rev., 40(1):49-84 (1988).
- 4. Beadle R. E. Summer pasture-associated obstructive pulmonary disease. In: Robinson N. E., ed. Current therapy in equine medicine. Philadelphia: W. B. Saunders Co., 512-516 (1983).
- 5. Bochner B. S., Busse W. W. Allergy and Asthma. J. Allergy Clin. Immunol., 115(5): 953-59 (2005).
- 6. Bowles K. S., Beadle R.E., Mouch S., Pourciau S. S., Littlefield-Chabaud M. A., Le Blanc C., Mistric L., Fermaglich D., Horohov D. W. A novel model for equine recurrent airway obstruction. Vet. Immunol. Immunopathol. 87(3-4):385-9 (2002).
- 7. Buechner-Maxwell V. Airway hyperresponsiveness. Equine respiratory disorders. The Compendium; 15:1379-1389 (1993).
- 8. Bureau F., Delhalle S., Bonizzi G., Fievez L., Dogne S., Kirschvink N., Vanderplasschen A., Merville M. P., Bours V., Lekeux P. Mechanism of persistent NF-Kappa B activity in the bronchi of an animal model of human asthma. J. Immunol., 165(10): 5822-5830 (2000).
- 9. Carlsson H. E., Lindberg A. A., Hammarström S. Titration of antibodies to salmonella O. antigens by enzyme-linked immunosorbent assay. Infect. Immun. 6(5):703-8 (1972).
- 10. Costa, L. R., Seahorn, T. L., Moore, R. M., Taylor, H. W., Oliver, J. L. and Hosgood, G. L. Correlation of clinical score, intrapleural pressure, cytologic findings of bronchoalveolar fluid, and histopathologic lesions of pulmonary tissue in horses with summer pasture-associated obstructive pulmonary disease. Am. J. Vet. Res. 61(2), 167-173 (2000).
- 11. Derksen F. J., Robinson, N. E. Overview of the equine respiratory system. In: Equine Respiratory Diseases, Ed. Lekeux P. International Veterinary Information Service (www.ivis.org), Ithaca, New York, USA, 2002.
- 12. Drazen J. M., Finn P. W., DeSanctis G. T. Mouse models of airway responsiveness. In: Annual Review of Physiology. Hoffman J. F., De Weer P. (eds). Annual Reviews, Inc., Calif., 61: 593-625 (1999).
- 13. Drazen J. M. Introduction to mediators of inflammation. Leff A(ed). In: Pulmonary and Critical Care Pharmacology and Therapeutics. McGraw-Hill, New York, 119-123 (1996).
- 14. Drazen J. M. Physiologic basis and interpretation of common indices of respiratory mechanical function. Environ. Health Prespective, 16: 11-16 (1976).
- 15. Drazen J. M, Takebayashi T., Long N. C., DeSanctis G. T., Shore S. A. Animal models of asthma and chronic bronchitis. Clin. Experiment. Allergy, 29: 37-47 (1999).
- 16. Drazen J. M, Venugopal C. S., Soter N. A. H2 receptor mediated inhibition of immediate type hypersensitivity reactions in vivo. Am. Rev. Respir. Dis., 117: 479-484 (1978).
- 17. Garland S. M., Locarnini S. A., Gust I. D. A solid-phase enzyme-linked immunosorbent assay (ELSIA) for detection of antibody to rubella virus. Pathology. 11:393-9 (1979).
- 18. Harada M., Magara-Koyanagi K., Watarai H., Nagata Y., Ishii Y., Kojo S., Horiguchi S., Okamoto Y., Nakayama T., Suzuki N., Yeh W. C., Akira S., Kitamura H., Ohara O., Seino K., Taniguchi M. IL-21-induced Bepsilon cell apoptosis mediated by natural killer T cells suppresses IgE responses. J. Exp. Med.; 203(13):2929-37 (2006).
- 19. Hargreave F. E., Dolovich J., O'Bryne M. B., et al., The origin of airway hyperresponsiveness. J. Allergy. Clin. Immunol., 78: 825-829 (1986).
- 20. Hart .L A., Krishnan V. L, Adcock I. M., Barnes P. J., Chung K. F. Activation and localization of transcription factor, nuclear factor Kappa B, in asthma. Am. Rev. Respir. Crit. Care Med., 158: 1585-1590 (1998).
- 21. Hjelm H., Hjelm K., Sjöquist J. Protein A from Staphylococcus aureus. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins. FEBS Lett. 28(1):73-6 (1972).
- 22. Horohov D. W., Beadle R. E., Mouch S., Pourciau S. S. Temporal regulation of cytokine mRNA expression in equine recurrent airway obstruction.108 (1-2):237-45 (2005).
- 23. Johansson S., Andersson K., Wennergren G., Wennerås C., Rudin A. CC16 inhibits the migration of eosinophils towards the formyl peptide fMLF but not towards PGD2. Inflammation. 32(2):65-9 (2009).
- 24. Katavolos P., Ackerley C. A., Viel L., Clark M. E., Wen X. AND Bienzle D. Clara Cell Secretary Protein Is Reduced in Equine Recurrent Airway Obstruction. Vet. Pathol. 46:604-613 (2009).
- 25. Krishnakumar S., Holmes E. P., Moore R. M., Kappel L., Venugopal C. S. Non-adrenergic, non-cholinergic excitatory innervation in asthma: Role of neurokinin-2 receptors. J. Auton. & Autacoid. Pharmacol., 22: 1-11 (2002).
- 26. Lee H. A., Kwon B., Hur G. Y., Choi S. J., Nahm D. H, Park H. S. Isotype and IgG subclass distribution of autoantibody response to alpha-enolase protein in adult patients with severe asthma. Yonsei Med. J.; 49(6):923-30 (2008).
- 27.
McGinnis 5, Madden T. L. BLAST: at the core of a powerful and diverse set of sequence analysis tools. Nucleic Acids Res. 1;32 (Web Server issue):W20-5 (2004). - 28. Morán G., Folch H., Araya 0., Burgos R., Barria M. Detection of reaginic antibodies against Faenia rectivirgula from the serum of horses affected with Recurrent Airway Obstruction by an in vitro bioassay, Vet. Res. Commun., 34(8):719-26 (2010).
- 29. K. Radon. The two sides of the “Endotoxin Coin”. Occup. Environ. Med.; 63:73-78 (2006)
- 30. Roy, S. R. Asthma. South. Med. J., 96(11):1061-67 (2003).
- 31. Seahorn T L, Beadle R E, McGorum B C, Marley C L. Quantification of antigen-specific antibody concentrations in tracheal lavage fluid of horses with summer pasture-associated obstructive pulmonary disease. Am. J. Vet. Res.; 58: 1408-1411 (1997).
- 32. Schmitz N., Dietmeier K., Bauer M., Maudrich M., Utzinger S., Muntwiler S., Saudan P., Bachmann M. F. Displaying Fel, d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J. Exp. Med.; 206(9):1941-55 (2009).
- 33. Snapper J. R. Large animal models of asthma. Am. Rev. Respir. Dis., 133: 351-352, (1986).
- 34. Venugopal C. S., Mendes, L. C. N., Peiro, J. R., Laborde, S., Stokes, A. M., Moore, R. M. Transcriptional changes associated with equine recurrent airway obstruction in affected and unaffected horses. Am. J. Vet. Res., 71(4):476-82 (2010).
- 35. Westritschnig K., Linhart B., Focke-Tejkl M., Pavkov T., Keller W., Ball T., Mari A., Hartl A., Stocklinger A., Scheiblhofer S., Thalhamer J., Ferreira F., Vieths S., Vogel L., Böhm A., Valent P., Valenta R. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Ph1 p 12, for the treatment of cross-sensitization to profilin. J Immunol. 179(11):7624-34 (2007).
- 36. Xia Y. C., Schuliga M., Shepherd M., Powell M., Harris T., Lagenbach S. Y., Tan P. S., Gerthoffer W. T., Hogarth P. M., Stewart A. G., Mackay G. A. Functional Expression of IgG-Fc Receptors in Human Airway Smooth Muscle Cells. Am. J. Respir. Cell Mol. Biol. (2010).
- 37. Yasuda, Y., Yoko Matsumura, Kazuki Kasahara, Noriko Ouji, Shigeki Sugiura, Keiichi Mikasa, and Eiji Kita. Microbial exposure early in life regulates airway inflammation in mice after infection with Streptococcus pneumoniae with enhancement of local resistance. Am. J. Physiol. Lung Cell Mol. Physiol. 298(1):L67-78 (2010).
- The complete disclosures of all references cited in this application are hereby incorporated by reference. In the event of an otherwise irreconcilable conflict, however, the present specification shall control.
Claims (29)
1. An isolated, purified peptide with an amino acid sequence that is at least 80% homologous to the sequence set forth in SEQ ID NO:1.
2. The isolated peptide of claim 1 , wherein said peptide has an amino acid sequence that is at least 85% homologous to the sequence set forth in SEQ ID NO:1.
3. The isolated peptide of claim 1 , wherein said peptide has an amino acid sequence that is at least 95% homologous to the sequence set forth in SEQ ID NO:1.
4. The isolated peptide of claim 1 , wherein said peptide has a sequence as in SEQ ID NO:1.
5. A medical composition comprising the isolated peptide of claim 1 and a pharmaceutically acceptable carrier.
6. A vaccine for mammalian respiratory disorders comprising the isolated peptide of claim 1 .
7. The vaccine of claim 6 , wherein the peptide is covalently or non-covalently linked to a protein carrier.
8. The vaccine of claim 7 , wherein the protein carrier is keyhole limpet hemocyanin.
9. The vaccine of claim 6 , wherein the peptide is administered with an adjuvant or other pharmaceutically acceptable compound.
10. The vaccine of claim 9 , wherein the adjuvant is incomplete Feund's adjuvant.
11. An isolated antibody to the peptide of claim 1 .
12. The antibody of claim 11 , wherein the antibody is a polyclonal antibody.
13. The antibody of claim 11 , wherein the antibody is a monoclonal antibody.
14. A method to treat or prevent a respiratory allergic disease in a mammal, said method comprising administering to the mammal a therapeutically effective amount of the vaccine of claim 4 .
15. The method of claim 12 , wherein the mammal is a horse.
16. The method of claim 12 , wherein the mammal is a human.
17. A method to increase treat or prevent respiratory airway disease in a mammal, said method comprising administering to the mammal a therapeutically effective amount of the antibody of claim 6 .
18. The method of claim 17 , wherein the mammal is a horse.
19. The method of claim 17 , wherein the mammal is a human.
20. A method to detect mammals that are susceptible to respiratory airway disease, said method comprising measuring the levels of CC10 protein in the serum of a mammal using the antibody of claim 11 .
21. The method of claim 20 , wherein said mammal is a horse.
22. The method of claim 20 , wherein said mammal is a human.
23. A method to detect mammals that are susceptible to respiratory airway disease, said method comprising measuring the levels of antibody to CC10 protein in the serum of a mammal using the isolated peptide of claim 1 .
24. The method of claim 23 , wherein the mammal is a horse.
25. The method of claim 23 , wherein the mammal is a human.
26. A DNA expression vector with a nucleic acid sequence encoding for the peptide as in claim 1 .
27. A method to treat or prevent a respiratory allergic disease in a mammal, said method comprising administering to the mammal a therapeutically effective amount of the DNA expression vector of claim 26 .
28. The method of claim 27 , wherein the mammal is a horse.
29. The method of claim 27 , wherein the mammal is a human.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/406,535 US20170190750A1 (en) | 2011-06-09 | 2017-01-13 | Peptide for Protection of Allergic Respiratory Disorders |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161494948P | 2011-06-09 | 2011-06-09 | |
PCT/US2012/041592 WO2012170842A2 (en) | 2011-06-09 | 2012-06-08 | Peptide for protection of allergic respiratory disorders |
US201314124297A | 2013-12-06 | 2013-12-06 | |
US15/406,535 US20170190750A1 (en) | 2011-06-09 | 2017-01-13 | Peptide for Protection of Allergic Respiratory Disorders |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/041592 Division WO2012170842A2 (en) | 2011-06-09 | 2012-06-08 | Peptide for protection of allergic respiratory disorders |
US14/124,297 Division US9546200B2 (en) | 2011-06-09 | 2012-06-08 | Peptide for protection of allergic respiratory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170190750A1 true US20170190750A1 (en) | 2017-07-06 |
Family
ID=47296766
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/124,297 Active US9546200B2 (en) | 2011-06-09 | 2012-06-08 | Peptide for protection of allergic respiratory disorders |
US15/406,535 Abandoned US20170190750A1 (en) | 2011-06-09 | 2017-01-13 | Peptide for Protection of Allergic Respiratory Disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/124,297 Active US9546200B2 (en) | 2011-06-09 | 2012-06-08 | Peptide for protection of allergic respiratory disorders |
Country Status (2)
Country | Link |
---|---|
US (2) | US9546200B2 (en) |
WO (1) | WO2012170842A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016012840A (en) | 2014-03-31 | 2017-05-09 | Boehringer Ingelheim Vetmedica Gmbh | Improved modular antigen transportation molecules and uses therof. |
CA2999930A1 (en) | 2015-09-30 | 2017-04-06 | Boehringer Ingelheim Vetmedica Gmbh | Improved modular antigen transportation molecules and uses therof in animals |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060281681A1 (en) | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
US6255281B1 (en) | 1997-05-28 | 2001-07-03 | Claragen, Inc. And U.S. Government | Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
US20050261180A1 (en) | 1997-05-28 | 2005-11-24 | Pilon Aprile L | Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
NZ588895A (en) | 2008-05-13 | 2012-07-27 | Clarassance Inc | Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis |
JP2011526916A (en) * | 2008-06-30 | 2011-10-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosus |
-
2012
- 2012-06-08 US US14/124,297 patent/US9546200B2/en active Active
- 2012-06-08 WO PCT/US2012/041592 patent/WO2012170842A2/en active Application Filing
-
2017
- 2017-01-13 US US15/406,535 patent/US20170190750A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20140105906A1 (en) | 2014-04-17 |
US9546200B2 (en) | 2017-01-17 |
WO2012170842A3 (en) | 2013-03-14 |
WO2012170842A2 (en) | 2012-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Niespodziana et al. | A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS | |
US11207375B2 (en) | Vaccines and compositions against Streptococcus pneumoniae | |
US10188717B2 (en) | Vaccines and compositions against Streptococcus pneumoniae | |
US20020009453A1 (en) | Polyclonal antibody composition for treating allergy | |
Mosbech et al. | Immunotherapy with yellow jacket venom: a comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified | |
KR100831118B1 (en) | Recombinant or purified polyclonal antibodies for treating allergy | |
WO2021233885A1 (en) | Mimotope peptides of the spike protein from the sars-cov-2 virus | |
US20170190750A1 (en) | Peptide for Protection of Allergic Respiratory Disorders | |
JP2021525754A (en) | Treatment of urticaria | |
US20220273793A1 (en) | Horse il-31 induced pruritus model | |
US20140235532A1 (en) | Immunogenic escherichia coli heat stable enterotoxin | |
JPWO2003020306A1 (en) | Desensitizer | |
WO2013191166A1 (en) | IgE PEPTIDE VACCINE | |
Newcomb et al. | Nasal immunization of asthmatic children with killed influenza virus | |
JP2869531B2 (en) | Refined mite allergen | |
RU2499605C1 (en) | Method for preparing polyclonal monospecific serum against human secretory immunoglobulin a | |
JP2023554138A (en) | Conjugated fumonisins to protect against mycotoxicosis | |
JPH06192299A (en) | Purified mite allergen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VENUGOPAL, CHANGARAM S.;PRAYAGA, SUDHIRDAS K.;SIGNING DATES FROM 20131204 TO 20131205;REEL/FRAME:041755/0454 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |